HPV vaccines for prevention of cervical pre-cancer in adolescent girls and women

Abstract

The evidence presented in this Cochrane meta-analysis shows the HPV vaccination confers significant benefit in preventing cervical pre-cancer. NNT of 60 for preventing one cervical pre-cancer (women 15 to 25 years old with or without HPV infection). The effect is higher for lesions associated with HPV16/18. The data also demonstrates an absence of serious adverse events. Therefore, we have assigned a color recommendation of Green (Benefit > Harm) to this vaccine.

Keywords

• HPV
• Vaccines
• Cervical pre-cancer
• cervical cancer
• adolescent